NEW YORK, Jan 16 – Curagen’s $124 million toxicogenomic and pharmacogenomic deal with Bayer and its $1.34 billion agreement to collaborate on drug targets for obesity and diabetes provide Curagen with the R&D budget necessary to enhance its portfolio of genomics tools and mine the genome for blockbuster drugs, analysts and company executives said Tuesday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.